Wednesday, 26 August 2026European Markets

GUILLEMOT Stock Went Down By Over 31% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of GUILLEMOT (CAC 40: GUI.PA) fell by a staggering 31.43% in 21 sessions from $13.52 to $9.27 at 17:02 EST on Tuesday, following the last session's downward trend. CAC 40 is sliding 0.07% to $7,132.35, following the last session's downward trend.

About GUILLEMOT

Guillemot Corporation S.A. designs, manufactures, and sells interactive entertainment hardware and accessories in France, Germany, the United Kingdom, Spain, the United States, Canada, Italy, China, Belgium, and Romania. It offers digital hardware and peripherals under the Hercules brand name; PC and console gaming accessories under the Thrustmaster brand name; and DJ solutions for various connected devices under the DJUCED brand name. Guillemot Corporation S.A. was founded in 1984 and is based in Chantepie, France.

Earnings Per Share

As for profitability, GUILLEMOT has a trailing twelve months EPS of $1.95.

PE Ratio

GUILLEMOT has a trailing twelve months price to earnings ratio of 4.75. Meaning, the purchaser of the share is investing $4.75 for every dollar of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

GUILLEMOT's stock is considered to be oversold (<=20).

Volume

Today's last reported volume for GUILLEMOT is 13565 which is 23.66% above its average volume of 10969.

More news about GUILLEMOT (GUI.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com